News

EO Launches First-Ever Digital Health Platform Offering Affordable, Clinician-Guided Cannabis Care

Bridging the Cannabis Care Gap with Personalized, Evidence-Based Medicine and Clinical Oversight at ScaleBOSTON, Aug. 17, 2022 (GLOBE NEWSWIRE) --…

2 years ago

Peggy’s Cove achieves top accessibility rating under the Rick Hansen Foundation Accessibility Certification™ program

Peggy's Cove (Nova Scotia), Aug. 17, 2022 (GLOBE NEWSWIRE) -- One of Nova Scotia’s most iconic attractions has achieved a…

2 years ago

Pure Extracts Delivers Its Largest Shipments to Launch its Newest Vape Product

VANCOUVER, British Columbia, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure…

2 years ago

Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

CARLSBAD, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for…

2 years ago

Blue Water Vaccines Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate

CINCINNATI, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a…

2 years ago

Oncotelic Participating at Biotechgate Digital Partnering

AGOURA HILLS, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments…

2 years ago

Oyster Point Pharma Announces TYRVAYA® To Be Covered By the Largest Medicare Pharmacy Benefit Manager

PRINCETON, N.J., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”),…

2 years ago

Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Trial builds on encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival…

2 years ago

Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors

CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed…

2 years ago